Physician profile
Goran Miljkovic
NPI 1053382416
$2,144.93
in general payments reported to CMS, 2019-2025
20 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $32.77 · 2021: $20.59 · 2022: $54.07 · 2023: $76.26 · 2024: $884 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $373.03 | 2024-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $322.05 | 2019-2025 | |
| Abbvie INC. | $279.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $180.93 | 2019-2024 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $156.11 | 2019-2022 | |
| Insmed, INC. | $155.56 | 2019-2025 | Arikayce |
| Janssen Products, LP | $99.95 | 2019 | |
| Lilly USA, LLC | $88.31 | 2019-2025 | Mounjaro, Zepbound |
| Emd Serono, INC. | $86.89 | 2019-2025 | Serostim |
| Paratek Pharmaceuticals, INC. | $67.91 | 2024-2025 | Nuzyra |
| Exact Sciences Corporation | $63.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $54.17 | 2024-2025 | Rybelsus, Ozempic |
| Theratechnologies INC. | $38.84 | 2024-2025 | Egrifta, Trogarzo |
| Cumberland Pharmaceuticals, INC. | $36.33 | 2019-2025 | Vibativ |
| Ferring Pharmaceuticals INC. | $32.65 | 2025 | Rebyota |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.36 | 2019 | |
| Csl Behring | $23.27 | 2019 | |
| Glaxosmithkline, LLC. | $21.44 | 2024 | Shingrix, Arexvy |
| Amgen INC. | $19.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.47 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goran Miljkovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.